clebopride has been researched along with Scleroderma, Systemic in 1 studies
clebopride: antidopaminergic; RN given refers to parent cpd; structure
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Benedetto, P | 1 |
| Liakouli, V | 1 |
| Ruscitti, P | 1 |
| Berardicurti, O | 1 |
| Carubbi, F | 1 |
| Panzera, N | 1 |
| Di Bartolomeo, S | 1 |
| Guggino, G | 1 |
| Ciccia, F | 1 |
| Triolo, G | 1 |
| Cipriani, P | 1 |
| Giacomelli, R | 1 |
1 other study available for clebopride and Scleroderma, Systemic
| Article | Year |
|---|---|
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy.
Topics: Adult; Antigens, CD; Antigens, Neoplasm; Benzamides; Cell Differentiation; Cell Proliferation; Cells | 2018 |